- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program2021 | First Faculty of Medicine
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | First Faculty of Medicine
- Small molecule drugs in the treatment of inflammatory bowel disease2018 | First Faculty of Medicine
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine